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Abstract
Aims Whether an exercise training intervention is associated with reduction in long-term high-sensitivity cardiac troponin T
(hs-cTnT) concentration (a biomarker of subclinical myocardial injury) in patients with heart failure with reduced ejection
fraction (HFrEF) is unknown. The aims were to determine (i) the effect of a 12 week endurance exercise training
intervention with different training intensities on hs-cTnT in stable patients with HFrEF (left ventricular ejection
fraction ≤ 35%) and (ii) associations between hs-cTnT and peak oxygen uptake (VO2peak).
Methods and results In this sub-study of the SMARTEX-HF trial originally including 261 patients from nine European centres,
213 eligible patients were included after withdrawals and appropriate exclusions [19% women, mean age 61.2 years (standard
deviation: 11.9)], randomized to high-intensity interval training (HIIT; n = 77), moderate continuous training (MCT; n = 63), or a
recommendation of regular exercise (RRE; n = 73). Hs-cTnT measurements and clinical data acquired before (BL) and after a
12 week exercise training intervention (12 weeks) and at 1 year follow-up (1 year) were analysed using multivariable mixed
models. Baseline hs-cTnT was above the 99th percentile upper reference limit of 14 ng/L in 35 (48%), 35 (56%), and 49
(64%) patients in the RRE, MCT, and HIIT groups, respectively. Median hs-cTnT was 16 ng/L at BL, 14 ng/L at 12 weeks, and
14 ng/L at 1 year. Hs-cTnT was statistically significantly reduced at 12 weeks in a model adjusted for randomization group,
centre and VO2peak, and after further adjustment in the final model that also included age, sex, creatinine concentrations,
N-terminal pro-brain natriuretic peptide, smoking, and heart failure treatment. The mean reduction from BL to 12 weeks in
the final model was 1.1 ng/L (95% confidence interval: 1.0–1.2 ng/L, P < 0.001), and the reduction was maintained at 1 year
with a mean reduction from BL to 1 year of 1.1 ng/L (95% confidence interval: 1.0–1.1 ng/L, P = 0.025). Randomization group
was not associated with hs-cTnT at any time point (overall test: P = 0.20, MCT vs. RRE: P = 0.81, HIIT vs. RRE: P = 0.095, inter-
action time × randomization group: P = 0.88). Independent of time point, higher VO2peak correlated with lower hs-cTnT (mean
reduction over all time points: 0.2 ng/L per increasing mL·kg1·min1, P = 0.002), without between-group differences (P = 0.19).
Conclusions In patients with stable HFrEF, a 12 week exercise intervention was associated with reduced hs-cTnT in all
groups when adjusted for clinical variables. Higher VO2peak correlated with lower hs-cTnT, suggesting a positive
long-term effect of increasing VO2peak on subclinical myocardial injury in HFrEF, independent of training programme.
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Introduction
Although exercise training is part of current guidelines for the
treatment of chronic heart failure (HF),1 concerns have been
raised that high-intensity exercise may increase myocardial
injury in patients with HF, where normal adaptive mecha-
nisms malfunction. In contrast, some studies indicate that ex-
ercise as a therapeutic option is underused in patients with
HF.2–4 Measurement of biomarkers of HF and myocardial in-
jury may help to clarify these issues. Cardiac-specific troponin
T (cTnT) is part of the contractile apparatus in cardiac muscle
cells and leaks out of damaged cells. It is therefore used as a
biomarker, and detection in serum plays an important role in
the diagnostics of acute and chronic myocardial injury.5
Chronic elevation of high-sensitivity cTnT (hs-cTnT) above
the 99th percentile upper reference limit of 14 ng/L is associ-
ated with adverse cardiovascular events.6,7 In chronic HF,
hs-cTnT also independently predicts more robust endpoints,
including all-cause and cardiovascular death, as well as car-
diovascular hospitalizations, with 18 ng/L as the preferred
cut-off.8
In patients diagnosed with HF, the effects and safety of
exercise training have been questioned.9,10 However, accord-
ing to the European Society of Cardiology 2016 HF guideline,
regular aerobic exercise training has the highest recommen-
dation in stable patients with HF with reduced ejection frac-
tion (HFrEF), with level of evidence class IA.4 An unresolved
matter is the preferred training intensity in these patients.
Peak oxygen uptake (VO2peak) is associated with prognosis
in HF,9,11 and high-intensity interval training (HIIT) has in-
creased VO2peak more efficiently than moderate continuous
training (MCT) in stable patients with HFrEF in some
studies.12 This was not confirmed in the index
SMARTEX-HF study, and the debate regarding training inten-
sity is therefore still ongoing.13
There are few studies assessing the association between
long-term cTnT concentrations and endurance exercise train-
ing in patients with HFrEF. In the HF-ACTION study evaluating
an exercise training programme in patients with stable HFrEF,
no changes were found in cTnT concentrations measured at
baseline, after 3 months, and after 12 months.14 However,
the employed assay was not a high-sensitivity assay (14% of
patients had measurable cTnT). In addition, only MCT with
a training duration of 15–35 min was performed, and the
training effect was too small to draw definite conclusions.
Accordingly, there is a need for studies using hs-cTnT assays
and high-intensity exercise training programmes with good
adherence.
The randomized multicentre SMARTEX-HF study compared
12 weeks of supervised intervention of HIIT, MCT, or a recom-
mendation of regular exercise (RRE, home-based). Training
intensity was measured objectively using heart rate (HR) at
all supervised training sessions, and myocardial injury was
assessed with hs-cTnT. The compliance to number of super-
vised sessions was 93.3%.13 Thus, these study data are well
suited for a secondary analysis investigating the association
between cTnT and endurance exercise training in patients
with HFrEF.
The aim of the present study was to determine the
long-term effect of a 12 week endurance exercise training in-
tervention with different training intensities and modes on
hs-cTnT in stable patients with HFrEF [left ventricular ejection
fraction (LVEF) ≤ 35%] and to determine associations
between hs-cTnT and VO2peak. We hypothesized (i) that a
12 week endurance exercise training programme is associ-
ated with reduced chronic myocardial injury, measured as a
decline in hs-cTnT concentrations and that this association
will last through the follow-up period; (ii) that different train-
ing intensities and modes have different associations to hs-
cTnT; and (iii) that changes in hs-cTnT during the study period
are associated with changes in VO2peak.
Methods
Patients
High-sensitivity cardiac troponin T was measured in a
sub-study of the SMARTEX-HF study that included 261
patients from nine different testing centres. Inclusion criteria
and interventions have been described in detail previously.15
Participants were randomized to three groups: HIIT (n = 90),
MCT (n = 85), and RRE (n = 86), stratified by testing centre
and ischaemic vs. non-ischaemic aetiology of HF. A total of
215 patients completed the 12 week follow-up, that is,
n = 77 in HIIT, n = 65 in MCT, and n = 73 in RRE. For the pres-
ent study, two patients were excluded due to missing blood
samples (both from the MCT group, n = 63 eligible patients).
Data were analysed according to the intention-to-treat princi-
ple, comprising 213 patients at baseline (BL) and 12 weeks
and 191 patients at 52 week follow-up (1 year). Study enrol-
ment, randomization, and loss to follow-up have been
detailed earlier.13 In brief, 14 patients had LVEF > 40% and
did not fulfil the inclusion criteria, 16 withdrew, died, or were
hospitalized before starting the training intervention, and 16
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were excluded during the training intervention (two died,
seven stopped due to serious adverse events, five withdrew,
and two were lost to follow-up). At 1 year, 5 had died, 6
missed follow-up due to serious adverse events, 1 withdrew,
1 was lost to follow-up, and 11 patients had missing blood
samples.13 In the present sub-study, total loss to follow-up
due to all causes was similar in the three groups (HIIT:
n = 10, MCT: n = 7, RRE: n = 7, P = 0.80).
Samples and tests
Blood samples were drawn after an overnight fast before
starting the training intervention (BL), after completion of
the exercise programme (12 weeks), and at 52 week
follow-up (1 year). Sampling was done more than 48 h after
the last exercise training. Serum hs-cTnT was measured in
all samples in a single batch at a core lab using a commer-
cially available assay (Elecsys TnT hs STAT, cobas e 801, Roche
Diagnostics). The analytical range was 3 to 10 000 ng/L, and
the inter-assay and intra-assay coefficients of variation in
the relevant concentration ranges were 2.1–3.5% and 2.2–
3.9%, respectively. The samples were analysed by order of
randomization number with the three samples from each
person in the same run, and the laboratory personnel were
blinded to randomization group. All samples had hs-cTnT
concentrations within the analytical range.
Cardiopulmonary exercise testing (CPET) was performed
after blood samples were drawn. As detailed in previous
publications, CPET was performed on either a bicycle or a
treadmill, using an incremental protocol with 10 or 20 W in-
crease in workload per minute until exhaustion, starting at 20
or 40 W, respectively. Standard equipment for indirect calo-
rimetry was used to measure the maximal oxygen uptake.
VO2peak is the highest measured oxygen uptake during CPET
when maximal oxygen uptake is not reached. The mean of
the three highest 10 s consecutive measurements was identi-
fied as VO2peak (mL·kg
1·min1), and for simplicity, the term
is used for all test results in the present study.13,15 BL,
12 weeks, and 1 year tests were performed using the same
protocol and exercise modality (treadmill or bicycle) as the
training. Left ventricular end-diastolic diameter (LVEDD) and
LVEF were assessed by echocardiography according to stan-
dard procedure, as detailed previously.13
Participants in the MCT and HIIT groups had three
supervised exercise training sessions per week, on a
treadmill or bicycle. Exercise protocols have been described
elsewhere.12,13,15 In brief, the HIIT group was targeted to
exercise at ≥90% of HRpeak during the high-intensity intervals
and 60–70% of HRpeak between these intervals. The MCT
group was targeted to exercise at 60–70% of HRpeak. The
number of participants was calculated based on the primary
endpoint in the index SMARTEX-HF study.15
The investigation was conducted in conformity with the
principles outlined in the Declaration of Helsinki.16 The study
was approved by national or institutional ethics committees
for medical research in all countries. All patients gave written
informed consent.
Statistics
This is a post hoc analysis of the SMARTEX-HF trial. Descrip-
tive data are given as median (25 and 75 percentiles). Due
to non-normality and to improve model fit, hs-cTnT concen-
trations were logarithmically transformed during analysis
and back-transformed to the original scale for data presenta-
tion. The changes in hs-cTnT and association to VO2peak
during the study were investigated using multivariable mixed
model analyses. This approach allows for variations in the
dependent and independent variables due to the repeated
measurements during the study and accounts for different
number of cases at each time point. A basic model included
hs-cTnT as dependent variable and VO2peak, randomization
group, and testing centre (by a categorical variable) as inde-
pendent variables. The model was then further adjusted
with predefined clinical variables selected based on previous
literature, that is, age,1,5 sex,1,5 creatinine concentration,1,17
N-terminal pro-brain natriuretic peptide (NT-proBNP),1
LVEDD,13 New York Heart Association (NYHA) functional
class,18 LVEF,18 HRpeak,
18 workload,18 and HF treatment,
defined as treatment (yes/no) with angiotensin II receptor
blockers, angiotensin-converting enzyme inhibitors, and/or
beta-blockers. For adjustment variables with repeated mea-
surements, that is, creatinine, NT-proBNP, LVEDD, LVEF, HR-
peak, and workload, the values for each time point were
included. Sex was a better explanatory variable than body
surface area. Non-significant variables were excluded from
the final model.
To assess the robustness of the results, two sensitivity
analyses were performed. Sensitivity analysis 1 investigated
whether supervised training had a different effect on
hs-cTnT than recommendation of exercise. Thus, data from
the exercise training groups were pooled, making one inter-
vention group (MCT + HIIT; n = 142) and one control group
(RRE; n = 73) in the analysis. In sensitivity analysis 2, we
included patients training ‘on target’, that is, 60–70% of HR-
peak in the MCT group and ≥90% of HRpeak in the HIIT group,
to better assess the effect of the target intensity difference
between the two training groups. All patients in the RRE
group were included in order to permit comparisons among
the three randomization groups.
Two-sided P-values < 0.05 were considered significant,
and Sidak adjustment was used where necessary for compar-
ison among the three randomization groups. Model fit was
assessed by checking residuals and using the Akaike informa-
tion criterion and Bayesian information criterion. These
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criteria indicate how well different models represent the
pattern in the data and penalize unnecessary variables and
interactions. Statistical analyses were performed using Stata,
Version 16 (StataCorp, College Station, TX).
Results
High-sensitivity cardiac troponin T concentrations
Descriptive data are shown in Table 1. Baseline concentra-
tions of hs-cTnT were above the 99th percentile upper refer-
ence limit in 35 (48%), 35 (56%), and 49 (64%) patients in the
RRE, MCT, and HIIT groups, respectively. Main testing results
are shown in Table 2. Hs-cTnT at any time point and changes
in hs-cTnT during the study period were not significantly as-
sociated with randomization group in the adjusted analysis
(overall test for randomization group: P = 0.20, MCT vs.
RRE: P = 0.81, HIIT vs. RRE: P = 0.095, interaction by time
and randomization group: P = 0.88) (Figure 1). Hs-cTnT con-
centrations decreased significantly by time, independently
of randomization group in both the basic and adjusted
models (overall test: basic model: P = 0.014, adjusted model:
P < 0.001). From BL to 12 weeks, mean reduction of hs-cTnT
was 1.1 ng/L (95% confidence interval: 1.0–1.2; P < 0.001) in
the model adjusted for clinical variables. The reduction was
maintained at 1 year in the adjusted model (from BL to 1 year:
1.1 ng/L, 95% confidence interval: 1.0–1.1; P = 0.025). There
was no significant difference between 12 weeks and 1 year
regarding hs-cTnT (P = 0.82).
Correlation between high-sensitivity cardiac
troponin T and peak oxygen uptake
Higher VO2peak correlated with lower hs-cTnT concentrations
for all time points, that is, BL, 12 weeks, and 1 year (mean
Table 1 Baseline characteristics
Characteristics RRE (n = 73) MCT (n = 63) HIIT (n = 77)
Age, years 60 (51–70) 60 (54–67) 65 (55–72)
Women, n (%) 14 (19.2%) 12 (19.1%) 14 (18.2%)
Heart failure < 12 months, n (%) 14 (19.4%) 7 (11.1%) 14 (18.2%)
New York Heart Association class, n (%)
II 54 (74.0%) 40 (63.5%) 55 (71.4%)
III 19 (26.0%) 23 (36.5%) 22 (28.6%)
Left ventricular ejection fraction, % 30.0 (23.9–33.9) 29.1 (23.5–34.0) 29.3 (24.0–34.0)
Ischaemic aetiology, n (%) 41 (56.2%) 37 (58.7%) 46 (59.7%)
History of myocardial infarction, n (%) 32 (43.8%) 34 (54.0%) 44 (57.1%)
History of coronary artery bypass surgery, n (%) 17 (23.3%) 13 (20.6%) 20 (26.0%)
History of percutaneous coronary intervention, n (%) 33 (45.2%) 21 (33.3%) 32 (41.6%)
Device therapy, n (%)
Pacemaker 2 (2.7%) 0 (0%) 2 (2.6%)
Implantable cardioverter defibrillator 31 (42.5%) 36 (57.1%) 27 (35.1%)
Cardiac resynchronization therapy 13 (17.8%) 4 (6.4%) 14 (18.2%)
Atrial fibrillation, n (%)
Paroxysmal 13 (17.8%) 5 (7.9%) 11 (14.3%)
Persistent 6 (8.2%) 8 (12.7%) 14 (18.2%)
History of hypertension, n (%) 36 (49.3%) 23 (36.5%) 22 (29.0%)
History of diabetes mellitus, n (%) 14 (19.2%) 20 (31.8%) 16 (20.8%)
History of chronic obstructive pulmonary disease, n (%) 4 (5.5%) 7 (11.1%) 4 (5.2%)
Smoking
Previous smoker 35 (48.0%) 30 (47.6%) 38 (49.4%)
Present smoker 18 (24.7%) 6 (9.5%) 14 (18.2%)
Alcohol consumption, units per week 1 (0–4) 2 (0–6) 1 (0–7)
Medications, n (%)
ACE inhibitor/ARB 70 (95.9%) 58 (92.1%) 71 (92.2%)
Beta-blockers 71 (97.3%) 59 (93.7%) 73 (94.8%)
Diuretics 51 (69.9%) 47 (74.6%) 58 (75.3%)
Digoxin or digitoxin 6 (8.2%) 7 (11.1%) 17 (22.1%)
Statins 45 (61.6%) 45 (71.4%) 50 (64.9%)
Anticoagulation 28 (38.4%) 20 (31.8%) 27 (35.1%)
Body mass index, kg/m2 27.7 (24.6–31.4) 27.5 (25.0–32.3) 27.6 (24.9–31.3)
Systolic blood pressure, mmHg 120 (110–131) 120 (110–131) 115 (105–129)
Diastolic blood pressure, mmHg 75 (70–82) 73 (65–80) 71 (65–80)
N-terminal pro-brain natriuretic peptide, ng/L 895 (407–1618) 976 (462–1635) 1052 (435–2285)
Left ventricular end-diastolic diameter, mm 68 (63–72) 69 (64–74) 68 (62–74)
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; HIIT, high-intensity interval training; MCT, moderate continu-
ous training; RRE, recommendations of regular exercise.
Data are given as median (25 and 75 percentiles) due to mostly non-normally distributed data or n (%) as indicated.
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reduction of hs-cTnT over all time points: 0.2 ng/L per in-
creasing mL·kg1·min1, P = 0.002, interaction by time:
P = 0.88), independent of randomization group (interaction
by randomization group: P = 0.19) (Figure 2). Because data
for each of the repeated measurements were included in
the mixed model, the design ensured that changes in VO2peak
for each patient were considered in parallel with changes in
hs-cTnT.
Clinical adjustment variables associated with higher
hs-cTnT were higher creatinine concentrations (P = 0.001),
higher age (P < 0.001), and higher NT-proBNP (P < 0.001)
(Figure 3). Variables associated with lower hs-cTnT were fe-
male sex (P < 0.001), ever smoking (P = 0.034), and treat-
ment with beta-blockers (P = 0.028). LVEDD (P = 0.098),
LVEF (P = 0.097), HRpeak (P = 0.39), NYHA (P = 0.59), and other
HF medications (P = 0.90) were not significantly associated
Figure 1 Mean high-sensitivity (hs) cardiac troponin T for each randomization group. (A) Measured concentrations. (B) Concentrations following ad-
justment for testing centre, randomization group, age, sex, creatinine, peak oxygen uptake, N-terminal pro-brain natriuretic peptide, left ventricular
end-diastolic diameter, and heart failure treatment. There were no significant differences among the groups. Hs-cardiac troponin T is
back-transformed from logarithmic values. *P < 0.05 compared with baseline in the same group. HIIT, high-intensity interval training; MCT, moderate
continuous training; RRE, recommendation of regular exercise.
Table 2 Main testing measures at baseline, 12 weeks, and 1 year with unadjusted changes
RRE (n = 73) MCT (n = 63) HIIT (n = 77)
Hs-cTnT, ng/L (95% CI)
Baseline 14 (12, 18) 15 (14, 18) 17 (15, 20)
12 week follow-up 12 (10, 15) 15 (13, 17) 16 (13, 19)
1 year follow-up 12 (10, 16) 14 (12, 17) 15 (12, 20)
Delta hs-cTnT, ng/L
Baseline to 12 week follow-up 0 (1, 0) 1 (2, 0) 1 (2, 0)
Baseline to 1 year follow-up 0 (1, 1) 1 (1, 0) 1 (1, 1)
VO2peak, mL·kg
1·min1 (95% CI)
Baseline 18.4 (16.8, 19.6) 16.2 (15.3, 18.7) 16.8 (15.8, 17.8)
12 week follow-up 17.4 (15.7, 19.8) 17.0 (15.7, 19.8) 18.2 (16.3, 20.0)
1 year follow-up 18.2 (15.8, 20.0) 16.2 (15.0, 18.6) 17.1 (15.5, 18.6)
Delta VO2peak, mL·kg
1·min1 (95% CI)
Baseline to 12 week follow-up 0.1 (0.9, 0.4) 1.1 (0.5, 1.8) 0.9 (0.0, 1.4)
Baseline to 1 year follow-up 0.4 (1.3, 0.4) 1.2 (0.2, 1.4) 0.1 (0.4, 1.0)
HIIT, high-intensity interval training; Hs-cTnT, high-sensitivity cardiac troponin T; MCT, moderate continuous training; RRE, recommenda-
tions of regular exercise; VO2peak, peak oxygen uptake.
Data are given as median with 95% confidence interval (CI) of the median due to non-normally distributed data.
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with hs-cTnT and were therefore not included in the final
model. Higher maximal workload during CPET was associated
with lower hs-cTnT when VO2peak was not included in the
model (P = 0.004), but VO2peak was a better explanatory
variable. Thus, to avoid collinearity, maximal workload was
not included in the final model. Model fit was considered
acceptable.
Sensitivity analyses
In the first sensitivity analysis, pooling of the two supervised
exercise training groups did not change the results: hs-cTnT
at any time point was not associated with randomization
group (P = 0.24); that is, there was no difference between
participants randomized to supervised exercise training and
those in the control group. In the second sensitivity analysis,
only including participants who trained ‘on target’, there was
no significant difference between the two training groups
(P = 0.76) and no significant difference between the training
groups and the control group (P = 0.83). However, only eight
patients (12.7%) in the MCT group trained on target at 60–
70% of HRpeak, and only 38 patients (49.4%) in the HIIT group
trained on target at ≥90% of HRpeak. As previously reported,
55 (86.3%) in the MCT group trained above the target,
whereas 39 (50.6%) in the HIIT group trained below the
target.13
Discussion
In this SMARTEX-HF sub-study of 213 patients with HFrEF un-
dergoing a 12 week endurance exercise training programme
or given recommendations for regular exercise, hs-cTnT con-
centrations were reduced at 12 weeks in all randomization
groups when adjusted for clinical variables. This reduction
was maintained at 1 year. Higher VO2peak correlated with
lower hs-cTnT concentrations independently of randomiza-
tion group and time point, suggesting reduced chronic sub-
clinical myocardial injury with increasing VO2peak. In other
words, the exercise programme by which the participants in-
creased their VO2peak was not decisive for the decrease in
hs-cTnT concentration.
Morris and Chen (2019) recently stated that cardiac reha-
bilitation and exercise are underused in patients with
HFrEF, despite robust scientific proof concerning safety
and inclusion in current guidelines.4 Other studies of car-
diac rehabilitation from European hospitals have shown
that cardiac rehabilitation is not offered to all eligible pa-
tients. Reasons given are primarily logistics and lack of re-
sources, but in some cases, the perception of lack of
safety has been stated.2,3 If HIIT were harmful to patients
with HFrEF over time, one would expect increases in
chronic myocardial injury, that is, hs-cTnT in this group,
which was not the case in the present study. Exercise train-
ing is generally recommended in chronic HF. However, tran-
sient increases in hs-cTnT after exercise training have
Figure 2 Association between high-sensitivity (hs) cardiac troponin T and peak oxygen uptake. The five groups correspond to the 10th, 25th, 50th,
75th, and 90th percentiles of peak oxygen uptake. Hs-cardiac troponin T is back-transformed from logarithmic values. *P < 0.05 compared with base-
line in the same group.
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been demonstrated, and there is an ongoing discussion
whether this represents a physiological response or a
pathological process indicating increased risk for future car-
diovascular events.19 In the present study, sampling was
performed more than 48 h after exercise training to avoid
confounding the evaluation of chronic myocardial injury
with such transient increases. Thus, differences in acute
transient increases of hs-cTnT among the randomization
groups cannot be assessed. The present study did not have
the necessary power to assess associations to serious ad-
verse events. Occurrence of serious adverse events has
been reported previously, and a brief summary is given in
the Supporting Information.13
As previously reported, many participants in the HIIT group
exercised below their prescribed target HR, whereas many
participants in the MCT group trained above their prescribed
target HR.13 This made the two supervised training interven-
tions more similar than intended and could thereby confound
the results. The sensitivity analyses supported the main re-
sults regarding associations between hs-cTnT and randomiza-
tion groups. They are also in line with a recent meta-analysis,
which found HIIT not to be superior to MCT regarding im-
provements in VO2peak in patients with HFrEF when isocaloric
protocols were compared.20
Published data showed that the RRE group also had an
improvement in VO2peak,
13 suggesting that many of the pa-
tients in the control group performed exercise as recom-
mended during the study period. However, there are no
objective data on how and how much the RRE group
exercised. There are several possible explanations why
patients in the RRE group also increased their VO2peak. Rec-
ommendations of regular exercise may be sufficient for
some patients to increase their daily activity. Additionally,
being part of a research study in which VO2peak was mea-
sured three times in 1 year may be an extra motivational
factor. This is supported by a recent study in a general
Figure 3 Associations between high-sensitivity (hs) cardiac troponin T and selected adjustment variables. (A) Age. (B) N-terminal pro-brain natriuretic
peptide. The five groups correspond to the 10th, 25th, 50th, 75th, and 90th percentiles of the respective adjustment variable. Hs-cTnT is
back-transformed from logarithmic values. *P < 0.05 compared with baseline in the same group.
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population of older adults, which showed that the control
group exercised with higher intensity than the MCT
group.21 Assuming that the RRE group followed the recom-
mendations they were given, the present study therefore
indicates that performing activities leading to improved
VO2peak, including supervised exercise training but not ex-
cluding other activities, is accompanied by reductions in
hs-cTnT in patients with HFrEF. The study also confirmed
the hypothesis that exercise training could lead to reduced
chronic subclinical myocardial injury as measured by hs-
cTnT, even if the mean absolute reduction was numerically
small. This may be related to the fact that the patients
were optimally medically treated or that the average po-
tential for cardiac improvement in the included patients
was not very large. Furthermore, there were individual dif-
ferences with larger effects in some patients, and hs-cTnT
increases in others. Despite the findings of reduced mean
myocardial injury, the present study did not show differ-
ences among HIIT, MCT, and RRE, suggesting that training
intensity and mode (supervised vs. home-based training)
did not affect chronic myocardial injury. These findings
are in line with the well-known positive effects of exercise
training on contractility and remodelling in skeletal
muscle.22
The SMARTEX-HF trial found that exercise training
increased VO2peak and reduced LVEDD.
13 The increase in
VO2peak was also associated with increased HRpeak from BL
to 12 weeks, the ability to increase workload during the
training period, lower NYHA class, higher LVEF, and lower
age. Thus, younger and less symptomatic patients had a
better training response than older and more symptomatic
patients.18 Of the factors previously associated with
increased VO2peak, only age was independently associated
with hs-cTnT concentrations in the present analysis. Effects
on hs-cTnT by the other mentioned factors could seem to
be mediated or confounded by VO2peak.
In the HF-ACTION study, no associations between cTnT and
exercise training were found when comparing a training
programme comprising 36 supervised sessions with usual
care.14 However, whereas the training programme in the
present study included three supervised exercise sessions
per week, each session lasting 37–48 min depending on the
training method, the 36 sessions in the HF-ACTION study took
place over a median time of 3.8 months and the participants
exercised a median time of 76 min/week during the first
3 months.14 Thus, there is reason to believe that the partici-
pants in the present study had a higher training load between
baseline and follow-up at 12 weeks. Myocardial injury in
HF-ACTION was measured using a contemporary cTnT analy-
sis and not the high-sensitivity assay. The combination of
higher compliance and intensity of the training programme
and the use of hs-cTnT in the present study enabled the
detection of small changes in cTnT concentrations during
the training period.
Clinical implications
Motivating patients with HFrEF to improve their VO2peak may
help reduce chronic myocardial injury as indicated by hs-
cTnT. HIIT did not seem to differ from MCT or RRE in this re-
spect, revealing that exercise intensity did not influence hs-
cTnT. Thus, cardiac rehabilitation in HFrEF should aim at find-
ing the optimal way to increase VO2peak for each individual
patient, including motivation and practical implementation
as important aspects.
Strengths and limitations
This was a large multicentre randomized controlled trial with
two different intervention groups and a control group where
the patients were recommended to perform exercise. The
intervention groups were closely followed and had good
adherence to number of sessions. However, the differences
between the training groups were smaller than anticipated
due to variability in training intensity and exercise response.
Physical activity data from the RRE group were limited. We
cannot exclude that these participants also trained with high
intensity. Blood samples were collected at times when the
potential interference from recent exercise was small; that
is, measured hs-cTnT was not biased from possible transient
increase related to exercise, as demonstrated in other
studies.23,24 Myocardial injury was measured using a highly
sensitive biomarker with high analytical precision. Because
samples were analysed in random order, small variations
due to measurement accuracy would not systematically
affect the results. The cardiac form of troponin T may be
expressed in damaged and regenerating skeletal muscle,25
which may result from exercise training. However, this would
tend to increase concentrations, contrary to the study results
showing decreased concentrations following the exercise
intervention.
Conclusions
In patients with stable HFrEF, a 12 week exercise training
intervention was associated with reduced serum hs-cTnT
concentrations in all randomization groups (HIIT, MCT,
and RRE) when adjusted for clinical variables. The effect
was maintained at 1 year follow-up. There was no signifi-
cant difference in chronic myocardial injury among patients
performing supervised training at high or moderate inten-
sity and those being recommended to exercise at home.
Those with higher VO2peak had lower hs-cTnT at all time
points. Increases in VO2peak were associated with reduc-
tions of myocardial injury, measured as hs-cTnT. The effect
was independent of randomization group and was
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maintained at 1 year follow-up, suggesting a long-term pos-
itive effect of increasing VO2peak in HFrEF regardless of
training method.
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